Human monoclonal antibodies to IFN-α for the treatment of autoimmune diseases

Expert Opinion on Therapeutic Patents

Volumn 16, Issue 2, 2006, Pages 221-226

[No Author Info available]

Author keywords

Autoimmune disease; IFN ; Immunomodulation; Monoclonal antibody (mAb); Systemic lupus erythematosus (SLE); Therapeutic mAb

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON ANTIBODY; ALPHA INTERFERON RECEPTOR 1 ANTIBODY; AUTOANTIBODY; BETA INTERFERON; FC RECEPTOR IIA ANTIBODY; INTERFERON; INTERFERON ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 13H5; MONOCLONAL ANTIBODY 13H7; MONOCLONAL ANTIBODY 7H9; OLIGONUCLEOTIDE; OMEGA INTERFERON; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; B LYMPHOCYTE DIFFERENTIATION; CELL MATURATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DRUG BINDING; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SPECIFICITY; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INTERFERON PRODUCTION; MULTIPLE SCLEROSIS; NONHUMAN; PATENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PSORIASIS; RECEPTOR BLOCKING; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; THYROIDITIS;

EID: 33144473938     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.2.221     Document Type: Article

References (58)

1. BEKISZ J, SCHMEISSER H, HERNANDEZ J, GOLDMAN ND, ZOON KC: Human interferons α, β and ω. Growth Factors (2004) 22:243-251.
2. THEOFILOPOULOS AN, BACCALA R, BEUTLER B, KONO DH: Type I interferons (α/β) in immunity and autoimmunity. Ann. Rev. Immunol. (2005) 23:307-336.
3. BRIERLEY MM, FISH EN: IFN-α/β receptor interactions to biologic outcomes: understanding the circuitry. J. Interferon Cytokine Res. (2002) 22:835-845.
4. PLATANIAS LC: Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. (2005) 5:375-386.
5. BARCHET W, CELLA M, COLONNA M: Plasmacytoid dendritic cells - virus experts of innate immunity. Semin. Immunol. (2005) 17:253-261.
6. ASSELIN-PATUREL C, TRINCHIERI G: Production of type I interferons: plasmacytoid dendritic cells and beyond. J. Exp. Med. (2005) 202:461-465.
7. SANTINI SM, DI PUCCHIO T, LAPENTA C et al.: The natural alliance between type I interferon and dendritic cells and its role in linking innate and adaptive immunity. J. Interferon Cytokine Res. (2002) 22:1071-1080.
8. POECK H, WAGNER M, BATTIANY J et al.: Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood (2004) 103:3058-3064.
9. BAECHLER EC, GREGERSEN PK, BEHRENS TW: The emerging role of interferon in human systemic lupus erythematosus. Curr. Opin. Immunol. (2004) 16:801-807.
10. CROW MK, KIROUM KA: Interferon-α in systemic lupus erythematosus. Curr. Opin. Rheumatol. (2004) 16:541-547.
11. SCHMIDT KN, OUYANG W: Targeting interferon-α: a promising approach for systemic lupus erythematosus therapy. Lupus (2004) 13:348-352.
12. BLANCO P, PALUCKA AK, GILL M, PASCUAL V, BANCHEREAU J: Induction of dendritic cell differentiation by LFN-α in systemic lupus erythematosus. Science (2001) 294:1540-1543.
13. BANCHEREAU J, PASCUAL V, PALUCKA AK: Autoimmunity through cytokine-induced dendritic cell activation. Immunity (2004) 20:539-550.
14. BENNETT L, PALUCKA AK, ARCE E et al.: Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. (2003) 197:711-723.
15. HAN GM, CHEN SL, SHEN N et al.: Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun. (2003) 4:177-186.
16. BAECHLER EC, BATLIWALLA FM, KARYPIS C et al.: Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA (2003) 100:2610-2615.
17. KIROU KA, LEE C, GEORGE S et al.: Coordinate overexpression of interferon-α-induced genes in systemic lupus erythematosus. Arthritis Rheum. (2004) 50:3958-3967.
18. KIROU KA, LEE C, GEORGE S et al.: Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. (2005) 52:1491-1503.
19. BAVE U, NORDMARK C, LOVGREN T et al.: Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum. (2005) 52:1185-1195.
20. DEVENDRA D, EISENBARTH GS: Interferon α - a potential link in the pathogenesis of viral-induced Type 1 diabetes and autoimmunity. Clin. Immunol. (2004) 111:225-233.
21. DEVENDRA D, JASINSKI J, MELANITOU E et al.: Interferon-α as a mediator of polyinosinic:polycytidylic acid-induced Type 1 diabetes. Diabetes (2005) 54:2549-2556.
22. PRUMMEL MF, LAURBERG P: Interferon-α and autoimmune thyroid disease. Thyroid (2003) 13:547-551.
23. NESTLE FO, CONRAD C, TUN-KYI A et al.: Plasmacytoid predendritic cells initiate psoriasis through interferon-α production. J. Exp. Med. (2005) 202:135-143.
24. STEWART TA: Neutralizing interferon α as a therapeutic approach to autoimmune diseases. Cytokine Growth Factor Rev. (2003) 14:139-154.
25. CHUNTHARAPAI A, LAI J, HUANG X et al.: Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: a candidate therapeutic for IDDM and SLE. Cytokine (2001) 15:250-260.
26. ISHIDA I, TOMIZUKA K, YOSHIDA H et al.: Production of human monoclonal and polyclonal antibodies in TransChromo animals. Cloning Stem Cells (2002) 4:91-102.
27. CHRISTEN U, MCGAVERN DB, LUSTER AD, VON HERRATH MG, OLDSTONE MB: Among CXCR3 chemokines, IFN-γ-inducible protein of 10 kDa (CXC chemokine ligand [CXCL] 10) but not monokine induced by IFN-γ (CXCL9) imprints a pattern for the subsequent development of autoimmune disease. J. Immunol. (2003) 171:6838-6845.
28. KOHRGRUBER N, GROGER M, MERANER P et al.: Plasmacytoid dendritic cell recruitment by immobilized CXCR3 ligands. J. Immunol. (2004) 173:6592-6602.
29. RHODE A, PAUZA ME, BARRAL AM et al.: Islet-specific expression of CXCL10 causes spontaneous islet infiltration and accelerates diabetes development. J. Immunol. (2005) 175:3516-3524.
30. H1-biased inflammation in cutaneous lupus erythematosus. J. Pathol. (2005) 205:435-442.
31. JEGO G, PASCUAL V, PALUCKA AK, BANCHEREAU J: Dendritic cells control B cell growth and differentiation. Curr. Dir. Autoimmun. (2005) 8:124-139.
32. CHEN J, BAIG E, FISH EN: Diversity and relatedness among the type I interferons. J. Interfron. Cytokine Res. (2004) 24:687-698.
33. HILKENS CM, SCHLAAK JF, KERR IM: Differential responses to IFN-α subtypes in human T cells and dendritic cells. J. Immunol. (2003) 171:5255-5263.
34. FOSTER GR, MASRI S, DAVID R et al.: IFN-α subtypes differentially affect human T cell motility. J. Immunol. (2004) 173:1663-1670.
35. STRONCEK DF, BASIL C, NAGORSEN D et al.: Delayed polarization of mononuclear phagocyte transcriptional program by type I interferon isoforms. J. Transl. Med. (2005) 3:24.
36. CHILL JH, QUADT SR, LEVY R, SCHREIBER G, ANGLISTER J: The human type I interferon receptor: NMR structure reveals the molecular basis of ligand binding. Structure (2003) 11:791-802.
37. COELHO LF, MAGNO DE FREITAS ALMEIDA G, MENNECHET FJ, BLANGY A, UZÉ G: Interferon-α and -β differentially regulate osteoclastogenesis: Role of differential induction of chemokine CXCL11 expression. Proc. Natl. Acad. Sci. USA (2005) 102:11917-11922.
38. MARKOWITZ C: Development of interferon-β as a therapy for multiple sclerosis. Expert Opin. Emerg. Drugs (2004) 9:363-374.
39. POLMAN CH, KAPPOS L, DAHLKE F et al.: Interferon β-1b treatment does not induce autoantibodies. Neurology (2005) 64:996-1000.
40. SCHWARTING A, PAUL K, TSCHIRNER S et al.: Interferon-β: a therapeutic for autoimmune lupus in MRL-Faslpr mice. J. Am. Soc. Nephrol. (2005) 16:3264-3272.
41. LI J, LIU Y, XIE C et al.: Deficiency of type I interferon contributes to Sle2-associated component lupus phenotypes. Arthritis Rheum. (2005) 52:3063-3072.
42. GOLDMAN LA, ZAFARI M, CUTRONE EC et al.: Characterization of antihuman IFN-AR-1 monoclonal antibodies: epitope localization and functional analysis. J. Interferon Cytokine Res. (1999) 19:15-26.
43. SANTIAGO-RABER ML, BACCALA R, HARALDSSON KM et al.: Type I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. (2003) 197:777-788.
44. HRON JD, PENG SL: Type I IFN protects against murine lupus. J. Immunol. (2004) 173:2134-2142.
45. RONNBLOM L, ALM GV: The natural interferon-α producing cells in systemic lupus erythematosus. Hum. Immunol. (2002) 63:1181-1193.
46. DZIONEK A, SOHMA Y, NAGAFUNE J et al.: BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon induction. J. Exp. Med. (2001) 194:1823-1834.
47. BLOMBERG S, ELORANTA ML, MAGNUSSON M, ALM GV, RONNBLOM L: Expression of the markers BDCA-2 and BDCA-4 and production of interferon-α by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Rheum. (2003) 48:2524-2532.
48. BAVE U, MAGNUSSON M, ELORANTA ML et al.: FcγRIIa is expressed on natural IFN-α-producing cells (plasmacytoid dendritic cells) and is required for the IFN-α production induced by apoptotic cells combined with lupus IgG. J. Immunol. (2003) 171:3296-3302.
49. MEANS TK, LATZ E, HAYASHI F et al.: Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest. (2005) 115:407-417.
50. TAN SARDJONO C, MOTTRAM PL, HOGARTH PM: The role of FcγRIIa as an inflammatory mediator in rheumatoid arthritis and systemic lupus erythematosus. Immunol. Cell Biol. (2003) 81:374-381.
51. TAN SARDJONO C, MOTTRAM PL, VAN DE VELDE NC et al.: Development of spontaneous multisystem autoimmune disease and hypersensitivity to antibody-induced inflammation in Fcγ receptor IIa-transgenic mice. Arthritis Rheum. (2005) 52:3220-3229.
52. VAN ROYEN-KERKHOF A, SANDERS EA, WALRAVEN V et al.: A novel human CD32 mAb blocks experimental immune haemolytic anaemia in FcγRIIA transgenic mice. Br. J. Haematol. (2005) 130:130-137.
53. BARRAT FJ, MEEKER T, GREGORIO J et al.: Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. (2005) 202:1131-1139.
54. AU WC, MOORE PA, LAFLEUR DW, TOMBAL B, PITHA PM: Characterization of the interferon regulatory factor-7 and its potential role in the transcription activation of interferon α genes. J. Biol. Chem. (1998) 273:29210-29217.
55. DAI J, MEGJUGORAC NJ, AMRUTE SB, FITZGERALD-BOCARSLY P: Regulation of IFN regulatory factor-7 and IFN-α production by enveloped virus and lipopolysaccharide in human plasmacytoid dendritic cells. J. Immunol. (2004) 173:1535-1548.
56. HONDA K, YANAI H, NEGISHI H et al.: IRF-7 is the master regulator of type I interferon-dependent immune responses. Nature (2005) 434:772-777.
57. SAMUEL CE: Antiviral actions of interferons. Clin. Microbiol. Rev. (2001) 14:778-809.
58. DECKER T, MULLER M, STOCKINGER S: The yin and yang of type I interferon activity in bacterial infection. Nat. Rev. Immunol. (2005) 5:675-687.